Sarepta Therapeutics (SRPT) stock price, revenue, and financials

Sarepta Therapeutics market cap is $6.4 b, and annual revenue was $540.1 m in FY 2020

$6.4 B

SRPT Mkt cap, 09-Sept-2021

$164.1 M

Sarepta Therapeutics Revenue Q2, 2021
Sarepta Therapeutics Net income (Q2, 2021)-81.4 M
Sarepta Therapeutics EBIT (Q2, 2021)-167.6 M
Sarepta Therapeutics Cash, 30-Jun-20211.7 B
Sarepta Therapeutics EV5 B
Get notified regarding key financial metrics and revenue changes at Sarepta TherapeuticsLearn more
Banner background

Sarepta Therapeutics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

4.5m3.0m4.2m6.1m2.6m1.1m16.3m35.0m46.0m64.6m73.5m78.5m87.0m94.7m99.0m113.7m137.4m143.9m146.9m164.1m

Cost of goods sold

252.0k534.0k

Gross profit

16.1m34.5m

Gross profit Margin, %

98%98%

R&D expense

17.8m15.6m14.8m13.8m13.0m21.1m20.9m20.6m21.9m39.2m29.2m36.7m38.8m44.3m34.3m29.1m58.9m34.2m46.2m122.8m86.6m90.6m113.3m133.9m136.1m188.5m190.4m195.1m239.6m

General and administrative expense

4.0m3.2m3.3m6.1m7.1m8.0m10.3m12.2m12.9m22.7m12.9m15.1m20.9m17.8m22.2m26.2m36.1m28.2m43.3m47.2m53.0m60.6m67.4m75.4m82.8m73.7m75.4m71.1m72.3m

Operating expense total

21.7m18.8m18.1m20.4m20.0m29.1m31.2m32.9m34.7m61.9m42.1m51.8m59.7m62.1m56.5m55.3m97.8m62.4m89.5m170.0m139.6m151.1m180.7m209.4m218.9m262.2m265.8m266.3m312.0m

Depreciation and amortization

780.0k216.0k217.0k216.0k216.0k217.0k216.0k166.0k165.0k166.0k

EBIT

(10.1m)(11.3m)(6.9m)(15.4m)(17.1m)(24.9m)(25.1m)(30.3m)(33.7m)(61.9m)(42.1m)(51.8m)(59.7m)(62.1m)(56.5m)(39.2m)(63.3m)(45.9m)(30.7m)(103.4m)(70.1m)(76.4m)(275.4m)(123.6m)(118.0m)(138.4m)(137.1m)(151.9m)(167.6m)

EBIT margin, %

(345%)(579%)(598%)(413%)(1172%)(3180%)(240%)(181%)(100%)(48%)(141%)(89%)(88%)(291%)(125%)(104%)(101%)(95%)(103%)(102%)

Interest expense

11.4m7.3m22.0k22.0k2.0m17.1m3.2m3.6m4.4m303.0k256.0k176.0k68.0k201.0k209.0k125.3m184.0k184.0k4.5m5.2m7.0m172.0k862.0k2.5m15.7m15.8m

Interest income

59.0k52.0k

Investment income

(19.0k)63.0k

Pre tax profit

86.1m(63.2m)(45.7m)(35.2m)(108.6m)(77.1m)(76.6m)(276.2m)(126.1m)(17.4m)(150.8m)(196.4m)(167.4m)(81.8m)

Income tax expense

2.0m(109.0k)2.0m139.0k622.0k(674.0k)84.0k174.0k226.0k115.0k20.0k96.0k(143.0k)(354.0k)

Net Income

1.3m(4.0m)(17.7m)(42.1m)(19.1m)(42.0m)(28.3m)(33.9m)(29.2m)(61.6m)(41.9m)(51.9m)(59.8m)(62.3m)(56.7m)84.1m(63.0m)(47.7m)(35.4m)(109.3m)(76.4m)(76.6m)(276.4m)(126.3m)(17.5m)(150.8m)(196.5m)(167.2m)(81.4m)

Sarepta Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

54.2m46.4m30.6m24.5m38.0m167.9m156.2m273.6m49.1m102.8m52.3m74.4m69.5m55.8m38.0m111.8m395.1m274.7m168.3m617.6m557.2m410.4m209.7m732.2m808.6m724.8m1.8b1.6b1.5b1.5b1.7b

Accounts Receivable

10.9m4.3m5.1m7.2m2.5m5.7m3.8m6.7m7.8m5.2m3.4m2.4m2.4m2.7m4.0m4.0m4.0m12.3m17.8m24.8m39.8m43.0m48.6m50.5m57.0m68.0m106.9m104.0m121.8m118.2m127.5m

Prepaid Expenses

943.0k1.3m1.9m1.6m1.7m3.0m5.7m2.8m9.1m15.9m26.4m24.4m23.1m19.5m16.9m15.3m22.0m22.7m28.6m27.0m31.2m43.0m54.8m136.2m110.8m79.0m

Inventories

2.9m30.4m41.8m64.7m99.4m104.1m115.8m140.5m156.6m166.4m173.2m179.7m220.1m240.3m268.8m

Current Assets

66.0m51.9m37.6m33.2m42.2m176.6m172.9m290.4m249.4m304.7m269.8m193.0m182.4m122.1m160.7m153.2m434.7m457.3m390.6m735.6m1.2b1.1b1.0b1.7b1.4b1.4b2.5b2.5b2.3b2.3b2.3b

PP&E

2.4m2.4m4.1m3.9m3.7m3.1m3.4m8.2m20.1m20.2m37.2m37.8m37.2m37.4m37.0m36.2m35.6m38.4m39.4m38.9m53.9m57.6m76.8m106.3m117.2m119.5m137.3m153.3m171.7m203.1m203.3m

Total Assets

74.9m61.1m46.6m42.1m53.1m193.3m183.6m304.5m275.4m337.3m319.1m242.7m231.7m184.8m213.4m204.1m487.3m511.5m450.1m800.3m1.3b1.2b1.2b2.0b1.7b1.7b2.9b2.9b2.8b2.8b2.8b

Accounts Payable

11.0m7.9m8.2m8.8m4.3m7.1m6.7m8.1m7.7m1.3m967.0k9.3m14.1m7.4m18.7m17.1m20.7m27.4m10.9m5.3m17.4m17.4m20.4m26.5m44.0m81.9m26.6m91.7m74.5m76.7m76.7m

Short-term debt

83.0k84.0k86.0k87.0k88.0k90.0k90.0k1.6m1.8m1.9m4.5m7.1m7.3m4.9m2.8m2.9m3.1m2.8m2.9m3.8m4.7m5.1m250.0m250.0m

Current Liabilities

36.9m26.5m29.9m17.1m55.2m103.7m92.4m51.1m37.8m29.4m22.7m33.9m39.0m37.7m55.2m66.9m64.9m74.6m66.0m70.5m91.2m104.7m114.4m137.4m162.1m215.9m306.4m354.9m378.4m364.7m425.0m

Long-term debt

1.8m1.8m1.7m1.7m1.7m1.6m1.6m1.6m1.6m1.5m3.8m1.5m415.4m52.2m50.2m49.7m753.2m766.6m768.7m60.7m65.3m

Non-Current Liabilities

1.0m1.0m967.0k757.0k758.0k755.0k757.0k4.8m

Total Debt

1.9m1.9m1.8m1.8m1.8m1.7m1.7m1.7m1.6m1.6m3.9m3.8m23.0m23.1m21.0m20.2m18.6m13.7m17.3m31.3m430.8m439.4m415.4m425.8m431.0m436.4m753.2m766.6m768.7m310.7m315.3m

Total Liabilities

106.1m94.8m57.5m46.4m37.4m32.9m41.9m66.3m61.5m74.4m82.6m78.7m82.4m72.4m103.1m523.5m548.1m543.1m615.3m648.6m707.3m1.8b1.8b1.9b2.2b2.3b

Common Stock

14.0k13.0k13.0k2.0k2.0k3.0k3.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k5.0k5.0k5.0k5.0k6.0k6.0k7.0k7.0k7.0k7.0k7.0k7.0k8.0k8.0k8.0k8.0k8.0k

Preferred Stock

Additional Paid-in Capital

339.7m340.3m341.7m342.1m364.6m560.6m581.2m781.4m800.5m905.3m920.9m941.4m947.8m957.6m1.1b1.1b1.5b1.5b1.5b1.9b2.0b2.1b2.1b3.0b3.0b3.1b3.5b3.5b3.6b3.5b3.5b

Retained Earnings

(605.4m)(634.6m)(740.6m)(782.4m)(834.4m)(958.8m)(1.0b)(1.1b)(1.1b)(1.1b)(1.2b)(1.3b)(1.4b)(1.4b)(1.7b)(1.9b)(2.1b)(2.3b)(2.5b)(2.7b)(3.0b)(3.0b)

Total Equity

35.1m31.8m14.0m22.5m(4.6m)87.3m88.8m247.0m229.0m299.9m286.2m200.8m165.4m123.2m139.0m121.5m408.6m429.1m377.8m697.2m776.8m699.0m639.8m1.3b1.1b995.2m1.1b1.0b892.0m535.4m485.1m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0.1 x0.2 x0.2 x0.2 x0 x0 x0 x0 x0.6 x0.6 x0.6 x0.3 x0.4 x0.4 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0.1 x0.1 x0.1 x0.1 x0 x0 x0 x0 x0.3 x0.4 x0.4 x0.2 x0.2 x0.3 x

Financial Leverage

2.1 x1.9 x3.3 x1.9 x-11.6 x2.2 x2.1 x1.2 x1.2 x1.1 x1.1 x1.2 x1.4 x1.5 x1.5 x1.7 x1.2 x1.2 x1.2 x1.1 x1.7 x1.8 x1.8 x1.5 x1.6 x1.7 x2.6 x2.8 x3.1 x5.2 x5.7 x

Sarepta Therapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

3.1m(908.0k)(17.7m)(9.7m)(59.2m)(42.1m)(61.1m)(103.2m)(28.3m)(62.1m)(91.4m)(61.6m)(103.4m)(155.3m)(59.8m)(122.1m)(178.8m)84.1m21.0m(26.7m)(35.4m)(144.6m)(221.0m)(76.6m)(353.0m)(479.4m)(17.5m)(168.3m)(364.8m)(167.2m)(248.7m)

Depreciation and Amortization

490.0k763.0k353.0k715.0k1.1m451.0k711.0k998.0k523.0k1.5m2.5m1.3m2.6m3.9m1.4m2.9m3.9m1.6m3.4m6.0m2.3m5.1m8.7m6.4m14.1m22.3m6.5m13.0m19.6m8.9m17.4m

Accounts Receivable

168.0k(317.0k)(13.0k)(5.0k)(9.0k)(7.0m)(12.6m)(19.5m)(10.4m)(13.5m)(19.1m)(1.5m)(7.9m)(19.0m)(16.0m)(13.1m)(30.9m)(16.9m)(26.2m)

Inventories

(2.9m)(17.6m)(28.9m)(51.9m)(15.8m)(20.5m)(32.2m)(15.0m)(31.1m)(40.9m)(1.8m)(8.3m)(48.7m)(8.4m)(36.8m)

Accounts Payable

(294.0k)1.9m1.7m(4.3m)(4.5m)(5.1m)(566.0k)(3.1m)

Cash From Operating Activities

(10.5m)(18.0m)(9.0m)(14.7m)(22.5m)(15.0m)(27.0m)(46.9m)(28.3m)(67.8m)(103.1m)(43.3m)(71.9m)(118.2m)(60.7m)(104.0m)(164.6m)(57.9m)(143.0m)(200.9m)(35.7m)(152.9m)(266.2m)(146.2m)(225.2m)(292.7m)627.8m520.2m282.0m(180.4m)(289.5m)

Purchases of PP&E

(676.0k)(973.0k)(9.0k)(143.0k)(108.0k)(9.0k)(435.0k)(1.8m)(5.3m)(9.8m)(22.3m)(532.0k)(1.2m)(2.3m)(1.2m)(1.6m)(2.4m)(4.5m)(7.3m)(8.1m)(12.2m)(20.9m)(41.0m)(16.3m)(32.9m)(42.4m)(9.1m)(28.3m)(53.6m)(21.1m)(27.0m)

Cash From Investing Activities

(1.2m)(1.5m)(262.0k)(641.0k)(722.0k)(7.7m)(9.2m)(10.8m)(182.3m)(185.2m)(205.7m)43.8m47.2m78.2m19.4m98.4m108.6m210.0m189.9m314.9m(14.3m)(69.4m)(132.8m)135.2m287.6m269.6m(17.7m)(51.9m)2.2m156.7m477.7m

Long-term Borrowings

(40.0k)(61.0k)(21.0k)(42.0k)(64.0k)(22.0k)(45.0k)(67.0k)(23.0k)(47.0k)(70.0k)(25.0k)(49.0k)(2.6m)(2.5m)(2.6m)(5.1m)(2.5m)(5.1m)(38.1m)(101.4m)(174.9m)(219.9m)

Cash From Financing Activities

32.3m32.3m(20.0k)(41.0k)21.3m3.0m4.7m143.7m2.7m98.7m104.1m406.0k20.7m22.2m(1.0m)37.1m370.8m206.0k(968.0k)381.3m7.5m32.8m8.9m377.6m383.9m385.6m319.0m336.6m355.4m2.9m6.4m

Net Change in Cash

20.6m12.8m(9.3m)(15.4m)(1.9m)(19.7m)(31.5m)86.0m(207.9m)(154.2m)(204.7m)885.0k(4.0m)(17.7m)(42.3m)31.5m314.8m152.3m45.9m495.2m(189.5m)(390.1m)366.6m446.2m362.6m929.1m804.9m639.6m(20.8m)194.6m

Interest Paid

45.0k68.0k22.0k43.0k65.0k22.0k102.0k123.0k20.0k40.0k60.0k18.0k37.0k359.0k409.0k828.0k1.2m291.0k538.0k924.0k853.0k6.1m6.9m4.3m4.3m5.4m15.0m20.5m11.7m27.8m

Sarepta Therapeutics Ratios

USDQ2, 2011

Financial Leverage

2.1 x

Sarepta Therapeutics Employee Rating

3.561 votes
Culture & Values
4
Work/Life Balance
3.6
Senior Management
3.8
Salary & Benefits
4.3
Career Opportunities
4
Source